Mylan Says Novartis' Lotrel Patent Invalid
Mylan filed its answer and counterclaim Tuesday in the U.S. District Court for the District of New Jersey. It joined other generics makers, like Par Pharmaceuticals and Lupin Ltd., that have claimed the Lotrel patent is not valid.
Novartis sued Mylan on Oct. 11 over Mylan's bid to enter Lotrel's billion-dollar annual market. Novartis asserted U.S. Patent Number 6,162,802,...
To view the full article, register now.